MedTrace Logo

Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab

NCT00864838 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2009-03-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.

Conditions

Interventions

DRUG

Acetazolamide

250 mg 1 hour before intravitreal injection

DRUG

Brimonidine tartarate

1 drop 1 hour before intravitreal injection

PROCEDURE

Anterior chamber paracentesis

Immediately after bevacizumab injection

Sponsors & Collaborators

  • Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP

    collaborator UNKNOWN

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Rodrigo Jorge, MD · University of Sao Paulo

  • Marco A Bonini-Filho, MD · University of Sao Paulo

  • Bianka Y Katayama, MD · Clinic´s Hospital, Ribeirão Preto Medical School, University of São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-02-28
Completion
2009-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00864838 on ClinicalTrials.gov